The DOI matches its Crossref record; 479 of the 479 references it cites were found in a registry or an index.
EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis
Open accessAbstract
Summary The natural history of cirrhosis is characterised by an asymptomatic compensated phase followed by a decompensated phase, marked by the development of overt clinical signs, the most frequent of which are ascites, bleeding, encephalopathy, and jaundice. The following Clinical Practice Guidelines (CPGs) represent the first CPGs on the management of decompensated cirrhosis. In this context, the panel of experts, having emphasised the importance of initiating aetiologic treatment for any degree of hepatic disease at the earliest possible stage, extended its work to all the complications of cirrhosis, which had not been covered by the European Association for the Study of the Liver guidelines, namely: ascites, refractory ascites, hyponatremia, gastrointestinal bleeding, bacterial infections, acute kidney injury, hepatorenal syndrome, acute-on-chronic liver failure, relative adrenal failure, cirrhotic cardiomyopathy, hepatopulmonary syndrome, and porto-pulmonary hypertension. The panel of experts, produced these GPGs using evidence from PubMed and Cochrane database searches providing up to date guidance on the management of decompensated cirrhosis with the only purpose of improving clinical practice.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The third international consensus definitions for sepsis and septic shock (Sepsis-3).
Singer, M., Deutschman, C. S., Seymour, C. W., Shankar-Hari, M., Annane, D., Bauer, M., Bellomo, R., Bernard, G. R., Chiche, J.-D., Coopersmith, C. M., et al. (2016) · JAMA · doi:10.1001/jama.2016.0287 · Cited by 28,250
Magiorakos, A.-P., Srinivasan, A., Carey, R. B., Carmeli, Y., Falagas, M. E., Giske, C. G., Harbarth, S., Hindler, J. F., Kahlmeter, G., Olsson-Liljequist, B., et al. (2012) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2011.03570.x · Cited by 14,449
Lang, R. M., Bierig, M., Devereux, R. B., Flachskampf, F. A., Foster, E., Pellikka, P. A., Picard, M. H., Roman, M. J., Seward, J., Shanewise, J. S., et al. (2005) · Journal of the American Society of Echocardiography · doi:10.1016/j.echo.2005.10.005 · Cited by 11,318
KDIGO Clinical Practice Guidelines for Acute Kidney Injury
Khwaja, A. (2012) · Nephron Clinical Practice · doi:10.1159/000339789 · Cited by 8,014
Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury
Mehta, R. L., Kellum, J. A., Shah, S. V., Molitoris, B. A., Ronco, C., Warnock, D. G., Levin, A., & the Acute Kidney Injury Network (2007) · Critical Care · doi:10.1186/cc5713 · Cited by 7,048
Nagueh, S. F., Smiseth, O. A., Appleton, C. P., Byrd, B. F., Dokainish, H., Edvardsen, T., Flachskampf, F. A., Gillebert, T. C., Klein, A. L., Lancellotti, P., et al. (2016) · Journal of the American Society of Echocardiography · doi:10.1016/j.echo.2016.01.011 · Cited by 5,262
Estimating glomerular filtration rate from serum creatinine and cystatin C
Inker, L. A., Schmid, C. H., Tighiouart, H., Eckfeldt, J. H., Feldman, H. I., Greene, T., Kusek, J. W., Manzi, J., Van Lente, F., Zhang, Y. L., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1114248 · Cited by 4,102
Expanding consensus in portal hypertension
de Franchis, R. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.05.022 · Cited by 3,078
Moreau, R., Jalan, R., Gines, P., Pavesi, M., Angeli, P., Cordoba, J., Durand, F., Gustot, T., Saliba, F., Domenicali, M., et al. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.02.042 · Cited by 3,020
Self-citationMalinchoc, M., Kamath, P. S., Gordon, F. D., Peine, C. J., Rank, J., & ter Borg, P. C. J. (2000) · Hepatology · doi:10.1053/he.2000.5852 · Cited by 2,893 · cited 1×
“A score system based on SCr, INR, serum bilirubin and aetiology of cirrhosis has been proposed to predict survival after TIPS insertion for refractory ascites [112].”
Background
Research works printed but not linked: 130
- Arroyo, 2007, Advances in the pathogenesis and treatment of type-1 and type-2 hepatorenal syndrome, J Hepatol, 46, 935, 10.1016/j.jhep.2007.02.001 · doi:10.1016/j.jhep.2007.02.001
- Alvarez, 2011, Long-term clinical course of decompensated alcoholic cirrhosis: a prospective study of 165 patients, J Clin Gastroenterol, 45, 906, 10.1097/MCG.0b013e3182284e13 · DOI
- Moreau, 2017, A randomized trial of 6-month norfloxacin therapy in patients with Child-Pugh class C cirrhosis, J Hepatol, 66, S1, 10.1016/S0168-8278(17)30264-7 · doi:10.1016/s0168-8278(17)30264-7
- Sola, 2017, Midodrine and albumin for prevention of complications of cirrhosis in patients in the waiting list for liver transplantation. A randomized, multicenter, double-blind, placebo-controlled trial, J Hepatol, 66, S11, 10.1016/S0168-8278(17)30285-4 · doi:10.1016/s0168-8278(17)30285-4
- Gerbes, 1991, Ascitic fluid analysis for the differentiation of malignancy-related and nonmalignant ascites. Proposal of a diagnostic sequence, Cancer, 68, 1808, 10.1002/1097-0142(19911015)68:8<1808::AID-CNCR2820680827>3.0.CO;2-6 · doi:10.1002/1097-0142(19911015)68:8<1808::aid-cncr2820680827>3.0.co;2-6
- Biselli, 2015, A new prognostic model to predict dropout from the waiting list in cirrhotic candidates for liver transplantation with MELD score <18, Liver Int, 35, 184, 10.1111/liv.12538 · doi:10.1111/liv.12538
- Lin, 2005, Should bleeding tendency deter abdominal paracentesis?, Dig Liver Dis, 37, 946, 10.1016/j.dld.2005.07.009 · doi:10.1016/j.dld.2005.07.009
- Cabrera, 1982, Aminoglycoside nephrotoxicity in cirrhosis. Value of urinary beta 2-microglobulin to discriminate functional renal failure from acute tubular damage, Gastroenterology, 82, 97, 10.1016/0016-5085(82)90129-9 · doi:10.1016/0016-5085(82)90129-9
- Guevara, 2004, Effects of contrast media on renal function in patients with cirrhosis: a prospective study, Hepatology, 40, 646, 10.1002/hep.20373 · doi:10.1002/hep.20373
- Saab, 2006, TIPS vs. paracentesis for cirrhotic patients with refractory ascites, Cochrane Database Syst Rev, CD004889
- Gaba, 2015, Survival benefit of TIPS vs. serial paracentesis in patients with refractory ascites: a single institution case-control propensity score analysis, Clin Radiol, 70, e51, 10.1016/j.crad.2015.02.002 · DOI
- Lenaerts, 2006, Effects of clonidine on diuretic response in ascitic patients with cirrhosis and activation of sympathetic nervous system, Hepatology, 44, 844, 10.1002/hep.21355 · doi:10.1002/hep.21355
- Singh, 2013, Midodrine and clonidine in patients with cirrhosis and refractory or recurrent ascites: a randomized pilot study, Am J Gastroenterol, 108, 560, 10.1038/ajg.2013.9 · doi:10.1038/ajg.2013.9
- Tandon, 2009, The effect of 1 month of therapy with midodrine, octreotide-LAR and albumin in refractory ascites: a pilot study, Liver Int, 29, 169, 10.1111/j.1478-3231.2008.01778.x · doi:10.1111/j.1478-3231.2008.01778.x
- Badillo, 2014, Hepatic hydrothorax. Clinical features, management, and outcomes in 77 patients and review of the literature, Medicine, 93, 135, 10.1097/MD.0000000000000025 · doi:10.1097/md.0000000000000025
- Garbuzenko, 2017, Hepatic hydrothorax: An update and review of the literature, World J Hepatol, 1197, 10.4254/wjh.v9.i31.1197 · doi:10.4254/wjh.v9.i31.1197
- Zenda, 1998, Detection of diaphragmatic defect as the cause of severe hepatic hydrothorax with magnetic resonance imaging, Am J Gastroenterol, 9, 2288, 10.1111/j.1572-0241.1998.00639.x · doi:10.1111/j.1572-0241.1998.00639.x
- Hewett, 2016, Diagnosis of isolated hepatic hydrothorax using peritoneal scintigraphy, Hepatology, 64, 1364, 10.1002/hep.28634 · doi:10.1002/hep.28634
- Alonso, 2010, Pleural effusion in liver disease, Semin Respir Crit Care Med, 31, 698, 10.1055/s-0030-1269829 · doi:10.1055/s-0030-1269829
- Xiol, 2005, Liver transplantation in patients with hepatic hydrothorax, Transpl Int, 18, 672, 10.1111/j.1432-2277.2005.00116.x · doi:10.1111/j.1432-2277.2005.00116.x
- Sersté, 2010, The impact of preoperative hepatic hydrothorax on the outcome of adult liver transplantation, Eur J Gastroenterol Hepatol, 22, 207, 10.1097/MEG.0b013e3283311140 · doi:10.1097/meg.0b013e3283311140
- Hou, 2016, Effectiveness and safety of pleurodesis for hepatic hydrothorax: A systematic review and meta-analysis, Dig Dis Sci, 61, 3321, 10.1007/s10620-016-4260-9 · doi:10.1007/s10620-016-4260-9
- Huang, 2016, Thoracoscopic mesh repair of diaphragmatic defects in hepatic hydrothorax: A 10-year experience, Ann Thorac Surg, 101, 1921, 10.1016/j.athoracsur.2015.11.023 · doi:10.1016/j.athoracsur.2015.11.023
- Cordoba, 2010, Hyponatremic and hepatic encephalopathies: similarities, differences and coexistence, Metab Brain Dis, 25, 73, 10.1007/s11011-010-9172-3 · DOI
- Garcia-Pagan, 2008, Review article: the modern management of portal hypertension–primary and secondary prophylaxis of variceal bleeding in cirrhotic patients, Aliment Pharmacol Ther, 28, 178, 10.1111/j.1365-2036.2008.03729.x · doi:10.1111/j.1365-2036.2008.03729.x
- Li, 2016, Carvedilol for portal hypertension in cirrhosis: systematic review with meta-analysis, BMJ Open, 6, e010902, 10.1136/bmjopen-2015-010902 · doi:10.1136/bmjopen-2015-010902
- Payance, 2016, Lack of clinical or haemodynamic rebound after abrupt interruption of beta-blockers in patients with cirrhosis, Aliment Pharmacol Ther, 43, 966, 10.1111/apt.13577 · doi:10.1111/apt.13577
- Villanueva, 2014, Optimizing general management of acute variceal bleeding in cirrhosis, Curr Hepatol Rep, 13, 198, 10.1007/s11901-014-0241-7 · doi:10.1007/s11901-014-0241-7
- Avgerinos, 1997, Early administration of somatostatin and efficacy of sclerotherapy in acute oesophageal variceal bleeds: the European Acute Bleeding Oesophageal Variceal Episodes (ABOVE) randomised trial, Lancet, 350, 1495, 10.1016/S0140-6736(97)05099-X · doi:10.1016/s0140-6736(97)05099-x
- Azam, 2012, Short course adjuvant terlipressin in acute variceal bleeding: a randomized double blind dummy controlled trial, J Hepatol, 56, 819, 10.1016/j.jhep.2011.11.019 · doi:10.1016/j.jhep.2011.11.019
- Rios Castellanos, 2015, Endoscopic injection of cyanoacrylate glue vs. other endoscopic procedures for acute bleeding gastric varices in people with portal hypertension, Cochrane Database Syst Rev, 5, CD010180
- Thuluvath, 2002, Portal Hypertensive gastropathy, Am J Gastroenterol, 97, 2973, 10.1111/j.1572-0241.2002.07094.x · doi:10.1111/j.1572-0241.2002.07094.x
- Yoshikawa, 1998, Effects of endoscopic variceal ligation on portal hypertensive gastropathy and gastric mucosal blood flow, Am J Gastroenterol, 93, 71, 10.1111/j.1572-0241.1998.071_c.x · doi:10.1111/j.1572-0241.1998.071_c.x
- Urrunaga, 2014, Portal hypertensive gastropathy and colopathy, Clin Liver Dis, 18, 389, 10.1016/j.cld.2014.01.008 · doi:10.1016/j.cld.2014.01.008
- Hosking, 1987, The role of propranolol in congestive gastropathy of portal hypertension, Hepatology, 7, 437, 10.1002/hep.1840070304 · doi:10.1002/hep.1840070304
- Ripoll, 2007, Treatment of gastropathy and gastric antral vascular ectasia in patients with portal hypertension, Curr Treat Options Gastroenterol, 10, 483, 10.1007/s11938-007-0048-5 · doi:10.1007/s11938-007-0048-5
- Kamath, 2000, Gastric Mucosal Responses to intrahepatic portosystemic shunting in patients with cirrhosis, Gastroenterology, 118, 905, 10.1016/S0016-5085(00)70176-4 · doi:10.1016/s0016-5085(00)70176-4
- Rios, 2015, Endoscopic injection of cyanoacrylate glue vs. other endoscopic procedures for acute bleeding gastric varices in people with portal hypertension, Cochrane Database Syst Rev, 5, CD010180
- Runyon, 2003, The evolution of ascitic fluid analysis in the diagnosis of spontaneous bacterial peritonitis. Runyon BA, Am J Gastroenterol, 98, 1675, 10.1111/j.1572-0241.2003.07600.x · doi:10.1111/j.1572-0241.2003.07600.x
- Gülberg, 2007, Insufficient sensitivity of reagent strips for spontaneous bacterial peritonitis, Hepatology, 46, 1669, 10.1002/hep.21856 · doi:10.1002/hep.21856
- Chen, 2011, Outcome predictors of cirrhotic patients with spontaneous bacterial empyema, Liver Int, 31, 417, 10.1111/j.1478-3231.2010.02447.x · doi:10.1111/j.1478-3231.2010.02447.x
- Garioud, 2017, J Clin Gastroenterol, 51, 831, 10.1097/MCG.0000000000000735 · doi:10.1097/mcg.0000000000000735
- Krag, 2010, Fluoroquinolones in the primary prophylaxis of spontaneous bacterial peritonitis, Am J Gastroenterol, 105, 1444, 10.1038/ajg.2010.126 · doi:10.1038/ajg.2010.126
- Arvaniti, 2010, Infections in patients with cirrhosis increase mortality four-fold and should be used in determining prognosis, Gastroenterology, 139, 1256, 10.1053/j.gastro.2010.06.019 · DOI · Paper page
- Fiore, 2017, Risk of spontaneousfungalperitonitis in hospitalized cirrhotic patients with ascites: a systematic review of observational studies and meta-analysis, Minerva Anestesiol, 83, 1309, 10.23736/S0375-9393.17.12034-1 · doi:10.23736/s0375-9393.17.12034-1
- Piano, 2017, Why and how to measure renal function in patients with liver disease, Liver Int, 37, 116, 10.1111/liv.13305 · DOI
- Roy, 1998, Glomerular filtration rate measurement in cirrhotic patients with renal failure, Clin Nephrol, 50, 342
- de Carvalho, 2012, Acute kidney injury network criteria as a predictor of hospital mortality in cirrhotic patients with ascites, J Clin Gastroenterol, 46, 21, 10.1097/MCG.0b013e31822e8e12 · doi:10.1097/mcg.0b013e31822e8e12
- 2012, Clinical practice guideline for the evaluation and management of chronic kidney disease, Kidny Int, 2013, 1
- Guevara, 2004, Effects of contrast media on renal function in patients with cirrhosis: a prospective study, Hepatology, 40, 646, 10.1002/hep.20373 · doi:10.1002/hep.20373
- Umgelter, 2009, Renal resistive index and renal function before and after paracentesis in patients with hepatorenal syndrome and tense ascites, Intensive Care Med, 35, 152, 10.1007/s00134-008-1253-y · doi:10.1007/s00134-008-1253-y
- Umgelter, 2008, Effects of plasma expansion with albumin and paracentesis on haemodynamics and kidney function in critically ill cirrhotic patients with tense ascites and hepatorenal syndrome: a prospective uncontrolled trial, Critical care, 12, R4, 10.1186/cc6765 · doi:10.1186/cc6765
- Qasem, 2014, Urinary biomarkers of acute kidney injury in patients with liver cirrhosis, ISRN Nephrol, 2014, 376795, 10.1155/2014/376795 · doi:10.1155/2014/376795
- Huelin, 2017, New diagnostic algorithm of acute kidney injury in cirrhosis that includes categorization of stage 1 and assessment of urine NGAL. Relevance for the differential diagnosis and clinical outcomes, J Hepatol, 66, S11, 10.1016/S0168-8278(17)30283-0 · doi:10.1016/s0168-8278(17)30283-0
- Wadei, 2008, Kidney allocation to liver transplant candidates with renal failure of undetermined etiology: role of percutaneous renal biopsy, Am J Transplant, 8, 2618, 10.1111/j.1600-6143.2008.02426.x · doi:10.1111/j.1600-6143.2008.02426.x
- Bairaktari, 2001, Partially reversible renal tubular damage in patients with obstructive jaundice, Hepatology, 33, 1365, 10.1053/jhep.2001.25089 · doi:10.1053/jhep.2001.25089
- van Slambrouck, 2013, Bile cast nephropathy is a common pathologic finding fo kidney injury associated with severe liver dysfunction, Kidney Int, 84, 192, 10.1038/ki.2013.78 · doi:10.1038/ki.2013.78
- Moreau, 2002, Terlipressin in patients with cirrhosis and type 1 hepatorenal syndrome: a retrospective multicenter study, Gastroenterology, 122, 923, 10.1053/gast.2002.32364 · doi:10.1053/gast.2002.32364
- Gerbes, 2009, Terlipressin for hepatorenal syndrome: continuous infusion as an alternative to i.v. bolus administration, Gastroenterology, 137, 1179, 10.1053/j.gastro.2009.03.064 · doi:10.1053/j.gastro.2009.03.064
- Piano, 2011, Continuousrecurrenceof type 1 hepatorenal syndrome and long-term treatment with terlipressin and albumin: a new exception to MELD score in the allocation system to liver transplantation?, J Hepatol, 55, 491, 10.1016/j.jhep.2011.02.002 · doi:10.1016/j.jhep.2011.02.002
- Gow, 2016, Outpatient terlipressin infusion for the treatment of refractory ascites, Am J Gastroenterol, 111, 1041, 10.1038/ajg.2016.168 · doi:10.1038/ajg.2016.168
- Duvoux, 2002, Effects of noradrenalin and albumin in patients with type I hepatorenal syndrome: a pilot study, Hepatology, 36, 374, 10.1053/jhep.2002.34343 · doi:10.1053/jhep.2002.34343
- Esrailian, 2007, Octreotide/Midodrine therapy significantly improves renal function and 30-day survival in patients with type 1 hepatorenal syndrome, Dig Dis Sci, 52, 742, 10.1007/s10620-006-9312-0 · doi:10.1007/s10620-006-9312-0
- Brensing, 2000, Long term outcome after transjugular intrahepatic portosystemic stent-shunt in non-transplant cirrhotics with hepatorenal syndrome: a phase II study, Gut, 47, 288, 10.1136/gut.47.2.288 · doi:10.1136/gut.47.2.288
- Testino, 2003, Type-2 hepatorenal syndrome and refractory ascites: role of transjugular intrahepatic portosystemic stent-shunt in eighteen patients with advanced cirrhosis awaiting orthotopic liver transplantation, Hepatogastroenterology, 50, 1753
- Sourianarayanane, 2014, Management and outcome in hepatorenal syndrome: need for renal replacement therapy in non-transplanted patients, Int Urol Nephrol, 46, 793, 10.1007/s11255-013-0527-7 · doi:10.1007/s11255-013-0527-7
- Trebicka, 2016, Predisposing factors in acute-on-chronic liver failure, Semin Liver Dis, 36, 167, 10.1055/s-0036-1583195 · doi:10.1055/s-0036-1583195
- Silva, 2015, Single-centre validation of the EASL-CLIF consortium definition of acute-on-chronic liver failure and CLIF-SOFA for prediction of mortality in cirrhosis, Liver Int, 35, 1516, 10.1111/liv.12597 · doi:10.1111/liv.12597
- Lee, 2015, CLIF-SOFA scoring system accurately predicts short-term mortality in acutely decompensated patients with alcoholic cirrhosis: a retrospective analysis, Liver Int, 35, 46, 10.1111/liv.12683 · DOI
- Chen, 2014, Dexamethasone in outcome of patients with hepatitis B virus-related acute-on-chronic liver failure, J Gastroenterol Hepatol, 29, 800, 10.1111/jgh.12454 · doi:10.1111/jgh.12454
- Guo, 2016, Short-term efficacy of treating hepatitis B virus-related acute-on-chronic liver failure based on cold pattern differentiation with hot herbs: A randomized controlled trial, Chin J Integr Med, 22, 573, 10.1007/s11655-016-2582-2 · doi:10.1007/s11655-016-2582-2
- De, 2003, Cardiac dysfunction in portal hypertension among patients with cirrhosis and non-cirrhotic portal fibrosis, J Hepatol, 39, 315, 10.1016/S0168-8278(03)00271-X · doi:10.1016/s0168-8278(03)00271-x
- Grose, 1995, Exercise-induced left ventricular dysfunction in alcoholic and non-alcoholic cirrhosis, J Hepatol, 22, 326, 10.1016/0168-8278(95)80286-X · doi:10.1016/0168-8278(95)80286-x
- Kim, 2010, Dobutamine stress echocardiography for evaluating cirrhotic cardiomyopathy in liver cirrhosis, Korean J Hepatol, 16, 376, 10.3350/kjhep.2010.16.4.376 · doi:10.3350/kjhep.2010.16.4.376
- Kozor, 2016, Insight into hypertrophied hearts: a cardiovascular magnetic resonance study of papillary muscle mass and T1 mapping, Eur Heart J Cardiovasc Imaging, 18, 1034, 10.1093/ehjci/jew187 · doi:10.1093/ehjci/jew187
- Ngu, 2016, Cardiac remodelling identified by cardiovascular magnetic resonance in patients with hepatitis C infection and liver disease, Int J Cardiovasc Imaging, 32, 629, 10.1007/s10554-015-0824-6 · doi:10.1007/s10554-015-0824-6
- Trevisani, 2012, QT interval prolongation by acute gastrointestinal bleeding in patients with cirrhosis, Liver Int, 32, 1510, 10.1111/j.1478-3231.2012.02847.x · doi:10.1111/j.1478-3231.2012.02847.x
- Zhao, 2016, Prevalence, risk factors and in-hospital outcomes of QTc interval prolongation in liver cirrhosis, Am J Med Sci, 352, 285, 10.1016/j.amjms.2016.06.012 · doi:10.1016/j.amjms.2016.06.012
- Raevens, 2014, Prevalence and outcome of diastolic dysfunction in liver transplantation recipients, Acta Cardiol, 69, 273, 10.1080/AC.69.3.3027830 · doi:10.1080/ac.69.3.3027830
- Saner, 2011, High brain-natriuretic peptide level predicts cirrhotic cardiomyopathy in liver transplant patients, Transpl Int, 24, 425, 10.1111/j.1432-2277.2011.01219.x · doi:10.1111/j.1432-2277.2011.01219.x
- Alexopoulou, 2012, Diastolic myocardial dysfunction does not affect survival in patients with cirrhosis, Transpl Int, 25, 1174, 10.1111/j.1432-2277.2012.01547.x · doi:10.1111/j.1432-2277.2012.01547.x
- Machicao, 2014, Pulmonary complications in chronic liver disease, Hepatology, 59, 1627, 10.1002/hep.26745 · doi:10.1002/hep.26745
- Kaymakoglu, 2003, Hepatopulmonary syndrome in noncirrhotic portal hypertensive patients, Dig Dis Sci, 48, 556, 10.1023/A:1022549018807 · doi:10.1023/a:1022549018807
- Rodríguez-Roisin, 1992, The hepatopulmonary syndrome: new name, old complexities, Thorax, 47, 897, 10.1136/thx.47.11.897 · doi:10.1136/thx.47.11.897
- Fallon, 2000, Pulmonary dysfunction in chronic liver disease, Hepatology, 32, 859, 10.1053/jhep.2000.7519 · doi:10.1053/jhep.2000.7519
- Schraufnagel, 2006, Structural and pathologic changes in the lung vasculature in chronic liver disease, Clin Chest Med, 17, 1, 10.1016/S0272-5231(05)70295-1 · doi:10.1016/s0272-5231(05)70295-1
- Boryczka, 2015, Influence of an upright body position on the size of intrapulmonary blood shunts in patients with advanced liver cirrhosis, J Physiol Pharmacol, 66, 855
- Fallon, 1997, The role of endothelial nitric oxide synthase in the pathogenesis of a rat model of hepatopulmonary syndrome, Gastroenterology, 113, 606, 10.1053/gast.1997.v113.pm9247483 · doi:10.1053/gast.1997.v113.pm9247483
- Luo, 2004, ET-1 and TNF- alpha in HPS: analysis in prehepatic portal hypertension and biliary and nonbiliary cirrhosis in rats, Am J Physiol Gastrointest Liver Physiol, 286, G294, 10.1152/ajpgi.00298.2003 · doi:10.1152/ajpgi.00298.2003
- Ling, 2004, The role of endothelin-1 and the endothelin B receptor in the pathogenesis of hepatopulmonary syndrome in the rat, Hepatology, 39, 1593, 10.1002/hep.20244 · doi:10.1002/hep.20244
- Tang, 2007, Modulation of pulmonary endothelial endothelin B receptor expression and signaling: implications for experimental hepatopulmonary syndrome, Am J Physiol Lung Cell Mol Physiol, 292, L1467, 10.1152/ajplung.00446.2006 · doi:10.1152/ajplung.00446.2006
- Frossard, 2007, Opposite regulation of endothelial NO synthase by HSP90 and caveolin in liver and lungs of rats with hepatopulmonary syndrome, Am J Physiol Gastrointest Liver Physiol, 293, G864, 10.1152/ajpgi.00136.2007 · doi:10.1152/ajpgi.00136.2007
- Chang, 2015, Rosuvastatin improves hepatopulmonary syndrome through inhibition of inflammatory angiogenesis of lung, Clin Sci, 129, 449, 10.1042/CS20140622 · doi:10.1042/cs20140622
- Rodriquez-Roisin, 2005, ERS (European Respiratory Society) Task ForcePHD Scientific Committee. Highlights of the ERS task force on pulmonary-hepatic vascular disorders (PHD), J Hepatol, 42, 924, 10.1016/j.jhep.2005.03.002 · doi:10.1016/j.jhep.2005.03.002
- Hoerning, 2014, Pulse oximetry is insufficient for timely diagnosis of hepatopulmonary syndrome in children with liver cirrhosis, J Pediatr, 164, 546, 10.1016/j.jpeds.2013.10.070 · doi:10.1016/j.jpeds.2013.10.070
- Köksal, 2006, Evaluation of intrapulmonary vascular dilatations with high-resolution computed thorax tomography in patients with hepatopulmonary syndrome, J Clin Gastroenterol, 40, 77, 10.1097/01.mcg.0000190775.57903.86 · doi:10.1097/01.mcg.0000190775.57903.86
- Lee, 1999, Hypoxemia and liver cirrhosis (hepatopulmonary syndrome) in eight patients: comparison of the central and peripheral pulmonary vasculature, Radiology, 211, 549, 10.1148/radiology.211.2.r99ma46549 · doi:10.1148/radiology.211.2.r99ma46549
- Abrams, 1995, Diagnostic utility of contrast echocardiography and lung perfusion scan in patients with hepatopulmonary syndrome, Gastroenterology, 109, 1283, 10.1016/0016-5085(95)90589-8 · doi:10.1016/0016-5085(95)90589-8
- Wolfe, 1977, Hypoxemia of cirrhosis: detection of abnormal small pulmonary vascular channels by a quantitative radionuclide method, Am J Med, 63, 746, 10.1016/0002-9343(77)90161-9 · doi:10.1016/0002-9343(77)90161-9
- Kalambokis, 2010, Pitfalls in the assessment of intrapulmonary shunt using lung perfusion scintigraphy in patients with cirrhosis, Liver Int, 31, 138, 10.1111/j.1478-3231.2010.02330.x · doi:10.1111/j.1478-3231.2010.02330.x
- Kochar, 2011, Serial pulse oximetry in hepatopulmonary syndrome, Dig Dis Sci, 56, 1862, 10.1007/s10620-011-1600-7 · DOI
- Tanikella, 2008, Pilot study of pentoxifylline in hepatopulmonary syndrome, Liver Transpl, 14, 1199, 10.1002/lt.21482 · doi:10.1002/lt.21482
- Gupta, 2008, Pentoxyfylline therapy for hepatopulmonary syndrome: a piloto study, Arch Intern Med, 168, 1820, 10.1001/archinte.168.16.1820 · doi:10.1001/archinte.168.16.1820
- De, 2010, The role of garlic in hepatopulmonary syndrome: a randomized controlled trial, Can J Gastroenterol, 24, 183, 10.1155/2010/349076 · doi:10.1155/2010/349076
- Tsauo, 2015, Role of transjugular intrahepatic portosystemic shunts in the management of hepatopulmonary syndrome: a systemic literature review, J Vasc Interv Radiol, 26, 1266, 10.1016/j.jvir.2015.04.017 · doi:10.1016/j.jvir.2015.04.017
- Poterucha, 1995, Failure of hepatopulmonary syndrome to resolve after liver transplantation and successful treatment with embolotherapy, Hepatology, 21, 96, 10.1002/hep.1840210117 · doi:10.1002/hep.1840210117
- Fallon, 2006, Model for end-stage liver disease (MELD) exception for hepatopulmonary syndrome, Liver Transpl, 12, S105, 10.1002/lt.20971 · doi:10.1002/lt.20971
- Fleming, 2008, Hepatopulmonary syndrome use of extracorporeal life support for life-threatening hypoxia following liver transplantation, Liver Transpl, 14, 966, 10.1002/lt.21477 · doi:10.1002/lt.21477
- Monsel, 2011, Extracorporeal membrane oxygenation as a brifge to liver trnsplantation for acute respiratory distress syndrome-induced life-threatening hypoxemia aggravated by hepatopulmonary syndrome, Crit Care, 15, R234, 10.1186/cc10476 · doi:10.1186/cc10476
- Chihara, 2011, Immediate nonivasive ventilation may improve mortality in patients with hepatopulmonary syndrome after liver transplantation, Liver Transpl, 17, 44, 10.1002/lt.22207 · doi:10.1002/lt.22207
- Torregrosa, 2001, Role of Doppler echocardiography in the assessment of portopulmonary hypertension in liver transplantation candidates, Transplantation, 71, 572, 10.1097/00007890-200102270-00015 · doi:10.1097/00007890-200102270-00015
- Cotton, 2002, Role of echocardiography in detecting portopulmonary hypertension in liver transplant candidates, Liver Transpl, 8, 1051, 10.1053/jlts.2002.35554 · doi:10.1053/jlts.2002.35554
- Paulus, 2013, Oestrogen and sexual Dimorphism of pulmonary arterial hypertension; a transitional challenge, Eur Respir J, 41, 1014, 10.1183/09031936.00021713 · doi:10.1183/09031936.00021713
- Condino, 2005, Portopulmonary hypertension in pediatric patients, J Pediatr, 147, 20, 10.1016/j.jpeds.2005.02.019 · doi:10.1016/j.jpeds.2005.02.019
- Ricci, 2007, Assessment of acute pulmonary vascular reactivity in portopulmonary hypertension, Liver Transpl, 13, 1506, 10.1002/lt.21173 · DOI
- Halank, 2004, Use of oral endothelin-receptor antagonist bosentan in the treatment of portopulmonary hypertension, Transplantation, 77, 1775, 10.1097/01.TP.0000122420.86904.89 · doi:10.1097/01.tp.0000122420.86904.89
- Cadden, 2009, The use of sildenafil to treat portopulmonary hypertension prior to liver transplantation, Ann Hepatol, 8, 158, 10.1016/S1665-2681(19)31798-3 · doi:10.1016/s1665-2681(19)31798-3
- Fisher, 2015, Effectiveness of phosphodiesterase-5 inhibitor therapy for portopulmonary hypertension, Can Respir J, 22, 42, 10.1155/2015/810376 · doi:10.1155/2015/810376
- Tzathas, 2002, Sildenafil (viagra) is a risk factor for acute variceal bleeding, Am J Gastroenterol, 97, 1856, 10.1111/j.1572-0241.2002.05876.x · doi:10.1111/j.1572-0241.2002.05876.x
- Sussman, 2006, Successful liver transplantation following medical management of portopulmonary hypertension: a single-center series, Am J Transplant, 6, 2177, 10.1111/j.1600-6143.2006.01432.x · doi:10.1111/j.1600-6143.2006.01432.x
- Melgosa, 2010, Acute and long-term effects of inhaled iloprost in portopulmonary hypertension, Liver Transpl, 16, 348, 10.1002/lt.21997 · doi:10.1002/lt.21997
- Colombato, 1996, Haemodynamic adaptation two months after transjugular intrahepatic portosystemic shunt (TIPS) in cirrhotic patients, Gut, 39, 600, 10.1136/gut.39.4.600 · doi:10.1136/gut.39.4.600
- Yoshida, 1993, Single-lung vs. liver transplantation for the treatment of portopulmonary hypertension–a comparison of two patients, Transplantation, 55, 688
- Mangus, 2013, Mild to moderate pulmonary hypertension in liver transplantation, J Surg Res, 184, 1150, 10.1016/j.jss.2013.04.040 · doi:10.1016/j.jss.2013.04.040
- Ramsay, 1997, Severe pulmonary hypertension in liver transplant candidates, Liver Transpl Surg, 3, 494, 10.1002/lt.500030503 · doi:10.1002/lt.500030503
- Krowka, 2006, Model for end-stage liver disease (MELD) exception for portopulmonary hypertension, Liver Transpl, 12, S114, 10.1002/lt.20975 · doi:10.1002/lt.20975
- Ramsay, 2010, Portopulmonary hypertension and right heart failure in patients with cirrhosis, Curr Opin Anaesthesiol, 23, 145, 10.1097/ACO.0b013e32833725c4 · doi:10.1097/aco.0b013e32833725c4
- Paulsen, 1989, Considerations for anesthetic management during veno-venous bypass in adult hepatic transplantation, Anesth Analg, 68, 489, 10.1213/00000539-198904000-00012 · doi:10.1213/00000539-198904000-00012
- Stratta, 2013, Extracorporeal membrane oxygenation rescue therapy in a case of portopulmonary hypertension during liver transplantation: a case report, Transplant Proc, 45, 2774, 10.1016/j.transproceed.2013.07.001 · doi:10.1016/j.transproceed.2013.07.001
- Khaderi, 2014, Long-term follow-up of portopulmonary hypertension patients after liver transplantation, Liver Transpl, 20, 724, 10.1002/lt.23870 · doi:10.1002/lt.23870
Cited by
Ginès, P., Krag, A., Abraldes, J. G., Solà, E., Fabrellas, N., & Kamath, P. S. (2021) · The Lancet · doi:10.1016/s0140-6736(21)01374-x · Cited by 1,663
Self-citationEASL Clinical Practice Guidelines on the management of hepatocellular carcinoma
Sangro, B., Argemi, J., Ronot, M., Paradis, V., Meyer, T., Mazzaferro, V., Jepsen, P., Golfieri, R., Galle, P., Dawson, L., et al. (2025) · Journal of Hepatology · doi:10.1016/j.jhep.2024.08.028 · Cited by 985
Mortality due to cirrhosis and liver cancer in the United States, 1999-2016: observational study
Tapper, E. B., & Parikh, N. D. (2018) · BMJ · doi:10.1136/bmj.k2817 · Cited by 856
Biggins, S. W., Angeli, P., Garcia‐Tsao, G., Ginès, P., Ling, S. C., Nadim, M. K., Wong, F., & Kim, W. R. (2021) · Hepatology · doi:10.1002/hep.31884 · Cited by 846
Self-citationManagement of Hepatocellular Carcinoma: A Review
Brown, Z. J., Tsilimigras, D. I., Ruff, S. M., Mohseni, A., Kamel, I. R., Cloyd, J. M., & Pawlik, T. M. (2023) · JAMA Surgery · doi:10.1001/jamasurg.2022.7989 · Cited by 763
Guidelines on the management of ascites in cirrhosis
Aithal, G. P., Palaniyappan, N., China, L., Härmälä, S., Macken, L., Ryan, J. M., Wilkes, E. A., Moore, K., Leithead, J. A., Hayes, P. C., et al. (2021) · Gut · doi:10.1136/gutjnl-2020-321790 · Cited by 680
Northup, P. G., Garcia‐Pagan, J. C., Garcia‐Tsao, G., Intagliata, N. M., Superina, R. A., Roberts, L. N., Lisman, T., & Valla, D. C. (2021) · Hepatology · doi:10.1002/hep.31646 · Cited by 667
Epidemiology and Effects of Bacterial Infections in Patients With Cirrhosis Worldwide
Piano, S., Singh, V., Caraceni, P., Maiwall, R., Alessandria, C., Fernandez, J., Soares, E. C., Kim, D. J., Kim, S. E., Marino, M., et al. (2019) · Gastroenterology · doi:10.1053/j.gastro.2018.12.005 · Cited by 516
Self-citationTerlipressin plus Albumin for the Treatment of Type 1 Hepatorenal Syndrome
Wong, F., Pappas, S. C., Curry, M. P., Reddy, K. R., Rubin, R. A., Porayko, M. K., Gonzalez, S. A., Mumtaz, K., Lim, N., Simonetto, D. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2008290 · Cited by 482
Angeli, P., Garcia-Tsao, G., Nadim, M. K., & Parikh, C. R. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.07.002 · Cited by 432
Self-citationEvidence-based clinical practice guidelines for Liver Cirrhosis 2020
Yoshiji, H., Nagoshi, S., Akahane, T., Asaoka, Y., Ueno, Y., Ogawa, K., Kawaguchi, T., Kurosaki, M., Sakaida, I., Shimizu, M., et al. (2021) · Journal of Gastroenterology · doi:10.1007/s00535-021-01788-x · Cited by 422
EASL Clinical Practice Guidelines on sclerosing cholangitis
Chazouilleres, O., Beuers, U., Bergquist, A., Karlsen, T. H., Levy, C., Samyn, M., Schramm, C., & Trauner, M. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.05.011 · Cited by 419
Hypoalbuminemia as Surrogate and Culprit of Infections
Wiedermann, C. J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094496 · Cited by 394
COVID-19 and liver disease: mechanistic and clinical perspectives
Marjot, T., Webb, G. J., Barritt, A. S., Moon, A. M., Stamataki, Z., Wong, V. W., & Barnes, E. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-021-00426-4 · Cited by 385
High rates of 30-day mortality in patients with cirrhosis and COVID-19
Iavarone, M., D'Ambrosio, R., Soria, A., Triolo, M., Pugliese, N., Del Poggio, P., Perricone, G., Massironi, S., Spinetti, A., Buscarini, E., et al. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.06.001 · Cited by 383
EASL Clinical Practice Guidelines on acute-on-chronic liver failure
Moreau, R., Tonon, M., Krag, A., Angeli, P., Berenguer, M., Berzigotti, A., Fernandez, J., Francoz, C., Gustot, T., Jalan, R., et al. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.04.021 · Cited by 375
Self-citationAlbumin in decompensated cirrhosis: new concepts and perspectives
Bernardi, M., Angeli, P., Claria, J., Moreau, R., Gines, P., Jalan, R., Caraceni, P., Fernandez, J., Gerbes, A. L., O'Brien, A. J., et al. (2020) · Gut · doi:10.1136/gutjnl-2019-318843 · Cited by 357
Self-citationA Randomized Trial of Albumin Infusions in Hospitalized Patients with Cirrhosis
China, L., Freemantle, N., Forrest, E., Kallis, Y., Ryder, S. D., Wright, G., Portal, A. J., Becares Salles, N., Gilroy, D. W., & O’Brien, A. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2022166 · Cited by 333
Villa, E., Bianchini, M., Blasi, A., Denys, A., Giannini, E. G., de Gottardi, A., Lisman, T., de Raucourt, E., Ripoll, C., & Rautou, P.-E. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2021.09.003 · Cited by 318
Transjugular intrahepatic portosystemic stent-shunt in the management of portal hypertension
Tripathi, D., Stanley, A. J., Hayes, P. C., Travis, S., Armstrong, M. J., Tsochatzis, E. A., Rowe, I. A., Roslund, N., Ireland, H., Lomax, M., et al. (2020) · Gut · doi:10.1136/gutjnl-2019-320221 · Cited by 314
Current treatment of non‐alcoholic fatty liver disease
Paternostro, R., & Trauner, M. (2022) · Journal of Internal Medicine · doi:10.1111/joim.13531 · Cited by 305
Liver diseases: epidemiology, causes, trends and predictions
Gan, C., Yuan, Y., Shen, H., Gao, J., Kong, X., Che, Z., Guo, Y., Wang, H., Dong, E., & Xiao, J. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02072-z · Cited by 310
Trebicka, J., Fernandez, J., Papp, M., Caraceni, P., Laleman, W., Gambino, C., Giovo, I., Uschner, F. E., Jansen, C., Jimenez, C., et al. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2020.11.019 · Cited by 304
Self-citationFernández, J., Clària, J., Amorós, A., Aguilar, F., Castro, M., Casulleras, M., Acevedo, J., Duran-Güell, M., Nuñez, L., Costa, M., et al. (2019) · Gastroenterology · doi:10.1053/j.gastro.2019.03.021 · Cited by 274
Self-citationNon-alcoholic fatty liver disease: A patient guideline
Francque, S. M., Marchesini, G., Kautz, A., Walmsley, M., Dorner, R., Lazarus, J. V., Zelber-Sagi, S., Hallsworth, K., Busetto, L., Frühbeck, G., et al. (2021) · JHEP Reports · doi:10.1016/j.jhepr.2021.100322 · Cited by 264
EASL Clinical Practice Guidelines on liver transplantation
Samuel, D., De Martin, E., Berg, T., Berenguer, M., Burra, P., Fondevila, C., Heimbach, J. K., Pageaux, G.-P., Sanchez-Fueyo, A., & Toso, C. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2024.07.032 · Cited by 263
Ginès, P., Solà, E., Angeli, P., Wong, F., Nadim, M. K., & Kamath, P. S. (2018) · Nature Reviews Disease Primers · doi:10.1038/s41572-018-0022-7 · Cited by 260
Self-citationPose, E., Napoleone, L., Amin, A., Campion, D., Jimenez, C., Piano, S., Roux, O., Uschner, F. E., de Wit, K., Zaccherini, G., et al. (2020) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(19)30320-6 · Cited by 154
APASL Covid-19 Task Force, Lau, G., & Sharma, M. (2020) · Hepatology International · doi:10.1007/s12072-020-10054-w · Cited by 88
“Surveillance for high risk varices is recommended for considering primary prophylaxis in patients with high risk of variceal bleeding [38].”
BackgroundCryoablation and Immunotherapy: An Enthralling Synergy to Confront the Tumors
Yakkala, C., Chiang, C. L.-L., Kandalaft, L., Denys, A., & Duran, R. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02283 · Cited by 88
Spatial transcriptomics identifies enriched gene expression and cell types in human liver fibrosis
Chung, B. K., Øgaard, J., Reims, H. M., Karlsen, T. H., & Melum, E. (2022) · Hepatology Communications · doi:10.1002/hep4.2001 · Cited by 85
Paternostro, R., Lampichler, K., Bardach, C., Asenbaum, U., Landler, C., Bauer, D., Mandorfer, M., Schwarzer, R., Trauner, M., Reiberger, T., et al. (2019) · Liver International · doi:10.1111/liv.14217 · Cited by 71
Human liver organoids: From generation to applications
Afonso, M. B., Marques, V., van Mil, S. W. C., & Rodrigues, C. M. P. (2024) · Hepatology · doi:10.1097/hep.0000000000000343 · Cited by 61
Acute-on-chronic liver failure: far to go—a review
Luo, J., Li, J., Li, P., Liang, X., Hassan, H. M., Moreau, R., & Li, J. (2023) · Critical Care · doi:10.1186/s13054-023-04540-4 · Cited by 54
Solà, E., Pose, E., Campion, D., Piano, S., Roux, O., Simon-Talero, M., Uschner, F., de Wit, K., Zaccherini, G., Alessandria, C., et al. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2020.08.009 · Cited by 41
“However, considering that guidelines do not recommend diuretic treatment for patients with grade 1 ascites and that the natural history of these patients is not well known, 82 patients with grade 1 ascites should not be included in trials.”
InfluentialSelf-citationAcute-on-chronic liver failure: Objective admission and support criteria in the intensive care unit
Dong, V., & Karvellas, C. J. (2019) · JHEP Reports · doi:10.1016/j.jhepr.2019.02.005 · Cited by 38
Insights on drug and gene delivery systems in liver fibrosis
Vyas, K., & Patel, M. M. (2023) · Asian Journal of Pharmaceutical Sciences · doi:10.1016/j.ajps.2023.100779 · Cited by 30
Top-Down Proteomics Identifies Plasma Proteoform Signatures of Liver Cirrhosis Progression
Forte, E., Sanders, J. M., Pla, I., Kanchustambham, V. L., Hollas, M. A. R., Huang, C.-F., Sanchez, A., Peterson, K. N., Melani, R. D., Huang, A., et al. (2024) · Molecular & Cellular Proteomics · doi:10.1016/j.mcpro.2024.100876 · Cited by 22
Qiu, T., Yang, J., Peng, C., Xiang, H., Huang, L., Ling, W., & Luo, Y. (2023) · Photoacoustics · doi:10.1016/j.pacs.2023.100562 · Cited by 15
Venkitaraman, A., De, A., Verma, N., Kumari, S., Leishangthem, B., Sharma, R. R., Kalra, N., Grover, S., & Singh, V. (2022) · Hepatology International · doi:10.1007/s12072-022-10314-x · Cited by 12
Zhang, W., Liu, L., Zhang, M., Zhang, F., Peng, C., Zhang, B., Chen, J., Li, L., He, J., Xiao, J., et al. (2021) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2020.00124 · Cited by 7
Wei, N., Du, L., Xiao, Z., Zhang, L., Zhou, Y., Gao, H., Liu, M., Wang, C., Hou, X., Li, Y., et al. (2025) · Experimental & Molecular Medicine · doi:10.1038/s12276-025-01554-6 · Cited by 3
Metadata
- Authors
- Angeli, P., Bernardi, M., Villanueva, C., Francoz, C., Mookerjee, R. P., Trebicka, J., Krag, A., Laleman, W., & Gines, P.
- Venue
- Journal of Hepatology
- Publisher
- Elsevier BV
- Published
- 2018-08
- Volume
- 69
- Issue
- 2
- Pages
- 406-460
- ISSN
- 0168-8278 (ISSN-L)
- OpenAlex
- W2802906787
- Cited by
- 2,905
- References
- 479
- FWCI
- 132.14
- Type
- journal article
- Language
- en
- Update notices
- erratum (2018-11-01)
- Open access
- bronze
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.